U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07291050) titled 'A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors' on Dec. 07.
Brief Summary: This is the first-in-human clinical study of TQB3217, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3217 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Cancer
Intervention:
DRUG: TQB3217Tablets
TQB3217 Tablets are ubiquitin specific peptidase 1(USP1)-t inhibitor.
Recruitment Status: NOT_Y...